INTRODUCTION
Tumor-assocla,ted antigens have been identified on a variety of human neoplasms. Each of these antigens may be able to serve as a target for an immune respOf.lse, the result of which would be eliminatjon of the tumor celL An essential component of this immune response is the presentation of antigen to potential effector cells. This can be accom plished via host professional antigen~presenting cells (APe)! such as dendritic cells, or via the tumor itself. The lack of information about tumor~associated antigens and their appar ent lack of immunogenicity in vivo complicate the induction of immune responses against breast cancers. We have undertaken the effort to increase the antigen-presenting cell (APe) function of a breast cancer line that expresses at least one tumor-associated anti gen, Her2/neu. The her2/neu gene encodes a ] 85-kd transmembrane tyrosine kinase recep tor that shares homology with the epidermal growth factor receptor. Previous studies indicated that Her2ineu was overexpressed by 20-30%1 of breast and ovarian tumors and its overexpression has been associated with a poor prognosis [1, 2] . Studies have a)so sug gested that Her2/neu can also function as a tumor-associated antigen. Cytotoxic T lympho cytes (CTL) isolated from ovarian tumors specifically recognizes Her2lneu-derived peptides and can kill Her2!neu+ tumors but not Her2!neu-tumors [3, 4] . Antibodies to Her2meu can be found in the sera of patients tvith metastatic breast cancer but not in con trol subjects [5, 6] . In addition, rats immunized w;th Her2!neu peptide, developed CD4+ I cell immune responses as well as antibody re:5ponses [7] and mice immunized with Her2/neu pep tides developed Her2/neu-specific tumor immunity [8] . Ihese data suggC5[ that vaccine strategies that :arget Her2!neu expressed by tumor cells are feasible but it is not known if immune responses to Her2/neu can be generated in humans in response to vaccination by antigen-bearing tumor cells.
The induction of antigen-specific T-cell immune responses is further complicated by [he fact that T-cell activation is dependent on a series of activation signals initialed aIld or chestrated by an antigen·presenting ce:L The professiona~ APC delivers an antigen-spe cific signal to the T-cell antigen receptor through complexes ofantigen:c peptide and HLA Class I molecules as well as an obligatory nonspecific cost;mu]atory signal that can be de livered to the I Cell CD28 receptor through CDSO (B7.1) [9] . Costimlliation through B7 induces IL-2 production and T-cell proliferation in both naive and memory T helper cells. Ihe coexpression of B7 and LFA-3 may provide optimal APC function since they can induce AP-l and KF-kappn B, transcription factors involved in the induction of several cy tokine gene promoters, that play an important rolt: in the regulation ofIL-2 gene transcrip tion [10j. Murine tumor models confirmed the importance ofB7-mcdiated costimulation in the generation of ami-tumor immune responses, \Vhen B7 was transfected into murine meianoma ceils, tumors grew poorly and could protect the host from J. subsequent chal lenge by the unmoditled parental tumor cell line [II, i2J. Depletion of CD8+ I Cells in vivo rEstored the growth rate comparable to the parenlal tumor. Since in vivo depietion of CD4+ T cells did not diminish the growth rate of the B7~transfectcd tumor cell line it is possible that B7 costimulated CD8+ CTL and bypassed the need for CD4-mediatcd T cell help. However, not aU [Umor:5 modified to express B7 can induce immunity A series of nonimmunogenic B7-modified tumors did not provide protective immunity nor did they augmenr CTL functiun, suggesting that tumor immunogenic~ry is a critical parameter in the development of tumor immunity [13) . The majodty of solid human tumors tested to date does not express 87 and are :herefore unable to deliver the costimulaLOry signals re quired for full I-cell activation. In the present srudy, we have genetically modified the hreast cancer eel! line MDA~M8-231 w express CD80. The CD80~rnodjfied ceHline was administered with G!v1-CSF as adjuvant [14J to patients with metastatic breast cancer to determine the toxicities of the vaccination protocol and nature of the immune response.
EXPERIMENTAL PROCEDURES/CLINICAL TRIAL DESIGN Patient Population
Breast cancer patients who Tested HLA-A2 positive and had metastatic disease were eligible for this study following s.igned informed consent, The restricrion of eligibility to HLA-A2+ patients is to permit the planned analysis of HLA-A2-restricred I cell immune responses following vaccmation. Patients must not have received more :hail. tvlO chemo~ therapy treatments for their n:etastatic disease !lad must have recove;:cd from ail side ef~ feets from the last chemo!herapy treatment.
Study Design
This study is designed to enroll 30 patients into one of six cohorts (5 patients/co ho:"t), Table 1 The tumor cell line MOA-MB-231 is an epIthelial breast tumor obtained from the ATCC [15] . It expresses Her2/neu, HLA-A2, CDS4 (ICAM-l) and C058 (LFA-3). The N cell line was transfected by Iipofeetion with pCMV-B7 (kindly provided by Dr. Robert Fenton) [16] . After transfection and se:ection in G418, the B7-modified MOA-MB-23I bulk culture was cloned by limiting dilution. One stably transfected clone was selected based on its growth raie l expression ofB7.1 (CDSO), lier2!oeu aod HLA-A2 and \Vas used ;case "\:",ere to develop our master cell bank, gibility to U immune Skin Tests 10 chemo ,11 side ef-
The parental and CD80-modified tumor ceUs used for s~jn testing were lethally irra diated (l 0,000 cGy), washed, counted and resuspended in 0.2 ml PBS+ 3% human serum albumin. Graded numbers ofceHs (10 4 ,10' and 10') specific ir Slides were then incubated with primary antibody overnight at 4'C. After washing, cells the sera 0 were incubated with anti-CD3 for identification of T cells or anti-CD20 for identification of B cells. Appropriate secondary biotinylated antibodies were then applied for 60 minutes treated wil antibodies at room temperature followed by the avidin-biotin-complex reagent. The peroxidase reac the produc lion was visualized by the chromogen 3,3'-diaminobenzidine (DAB).
an associa body respc
RESULTS
Ten patients have been enrolled in this trial and all ten were previously treated with DIscm chemotherapy andlor hormonal therapy. Their characteristics are listed in Table 2 . Nearly all patients received two different chemotherapy regimens for metastatic disease prjor to This study entry. While many patients had visceral metastases only four patients had metastatic breast can disease confined to bnne' only. Patients enrolled in cohort one received 3, 5, 3, 2 and 3 adjuvant ( vaccinations respectively before going off study due to progressive disease. Patients in co sponses it hort 2 received 3, 3, 6~ 3,5 vaccinations respectively.
Toxicities and Response
There have been no treatment-related deaths nor has any life threatening toxicity been observed. There have been grade 1 or 2 toxicities associated with the vaccination protocoL These are mamly flu-like symptoms and bone pain probably related to the ad ministration of OM-CSF. In addition, postoperative swelling and pain at the lymph node Immune Monitoring Studies to each To determine the capacity of parental tumor and CDSO-modified tumor to stimulate ish per a DTH type response, patients were injected subcutaneously with 10', 10' and 10' irradi was: de ated tumor cells, Forty-eight hours later, skin test reactions were evaluated, The pre-vac +4SD of cine skin test results for the first 10 patients are presented in Table 3 , There are no ly 1%, of statistically significant differences in the size of the skin test lesions betweeri skin test sites that received parental versus CDSO-modified tumor To determine the composition of the DTH reaction, punch biopsies were obtained in selected patients, Figure 1 , The skin test site was characterized by an extensive infiltration of eosinophil,. Furthermore, T cell infiltrates were present but only a rare B cell was observed in the skin test site. red and
One of the immunological endpoints of this study is the determination of Her2lneu
11 Serum.
specific immune responses. We have measured Her2/neu-specific antibody responses in ng, cells the sera of patients enrolled in cohort 1, Table 4 , Three of the first five patients to be ification treated with the CD80-modified tumor cell vaccine developed increased Her2ineu-specific minutes antibodies as detected by ELISA, Additional patient data will be required to determine if ase reac the production of antibodies is the result of the vaccination procedure and whether there is an association with Her2/neu expression by the patient's tumor and the titer of the anti body response.
.ted with DISCUSSION 2. Nearly , prior to This preliminary report of our ongoing vaccine study suggests that vaccination of letastatic breast cancer patients with CD80-modified tumor cells in combination with G!I,f-CSF as 2 and 3 adjuvant can induce cellular immune responses as weB as antigen-specific -antibody re~ ltS in cosponses in some 'patients. CeBular immune responses against the lIer2/neu receptor ex- pressed by tumor cells have been reported. These laboratory studies demonstrated that T cells copurified from solid ovarian tumor or malignant ascites could be serially stimulated to induce CTL function. Recently. these data were extended to include antibody responses in patients with breast cancer [6] . Although only 3/63 patients with tumors that expressed normalleve!s of Her2/neu had significant anti·Her2/neu antibody titers. 9/44 patients with tumors that overexpressed Her2!neu developed specific antireceptor antibodies. In this study. three of the first five patients vaccinated with CDSO-modified tumor registered in creased Her2!neu-specific antibodies although the antibody level in one patient was low titered. Further evidence of immune system stimulation was obtained from skjn test data. The majority of patient's skin tested prior to their first vaccination developed DTH-like re sponses to the CD80-modified tumor but not to the parental tumor. The results of punch biopsies obtained 48 hours after injection of CD80-modified tumor cells showed T-cell in fi]tration into the skin tesr site, In conrrast, B ce]]s were present but rare, Another feature 
CONCLUSIONS
This study has completed two of five cohorts and aecrued 10 of a total of 30 pa tients. The tOXIcities related to this treatment have been tolerable. The planned immune monitoring studics are not yet completed. Six of ren patients enrolled on this trial devel oped larger DTH reactions to CDSO-modified tumor relative to unmodified control but overall, no significant differences in DTH reaction sizes were noted. However, prelimi nary results suggest that in some patients, vaccination in combination with GM-CSF can induce antibody responses against the Her2ineu protein expressed by the vaccine cell line. At the completion of this stndy, we will determine the safety, tolerahility, and immu nologic effects of vaccination with CDBO-modified tumor cells + GM-CSF. 
